A one-month delay in starting methotrexate after the 13-valent pneumococcal conjugate vaccine (PCV13) does not compromise rheumatoid arthritis (RA) disease control, structural progression, or treatment escalation over a full year, according to an ancillary analysis of the VACIMRA trial.
The original trial had shown that postponing methotrexate for one month after PCV13 improved humoral vaccine responses at 1 and 12 months. This follow-up study provides critical reassurance for rheumatologists concerned about the early treatment window.
Researchers compared early RA patients who started methotrexate immediately with those who delayed initiation by one month after vaccination. They assessed disease activity using DAS28-ESR scores at Months 1, 2, 3, 6, and 12, and radiographic progression via the van der Heijde modified Sharp score on X-rays at inclusion, Month 6, and Month 12.
Among 96 analyzable patients from the Montpellier center, baseline characteristics were similar: mean age 58, baseline DAS28-ESR 4.88, and total modified Sharp score 1.53. At 12 months, remission rates were comparable-53.7% in the immediate group vs. 46.3% in the delayed group. Low disease activity rates also showed no significant difference (75.6% vs. 61.0%). DAS28-ESR scores were similar at Months 1 and 3, but favored the delay group at Month 6 and Month 12.
Structural outcomes were equally reassuring: modified Sharp score progression was comparable at both Month 6 and Month 12, indicating no greater radiographic damage in the delayed-start group over the first year.
The authors conclude that deferring methotrexate for one month after PCV13 may be a viable strategy to enhance vaccine immunity without undermining early RA outcomes. Clinicians can consider aligning early RA treatment with vaccine optimization in selected patients.